PL2119448T3 - Miejsce wiązania HGFR o wysokim powinowactwie oraz sposoby identyfikacji jego antagonistów - Google Patents
Miejsce wiązania HGFR o wysokim powinowactwie oraz sposoby identyfikacji jego antagonistówInfo
- Publication number
- PL2119448T3 PL2119448T3 PL09159644T PL09159644T PL2119448T3 PL 2119448 T3 PL2119448 T3 PL 2119448T3 PL 09159644 T PL09159644 T PL 09159644T PL 09159644 T PL09159644 T PL 09159644T PL 2119448 T3 PL2119448 T3 PL 2119448T3
- Authority
- PL
- Poland
- Prior art keywords
- hgfr
- antagonists
- identification
- methods
- binding site
- Prior art date
Links
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 title 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 abstract 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08103958 | 2008-05-14 | ||
| EP09159644A EP2119448B1 (en) | 2008-05-14 | 2009-05-07 | High affinity binding site of HGFR and methods for identification of antagonists thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2119448T3 true PL2119448T3 (pl) | 2011-11-30 |
Family
ID=40984839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09159644T PL2119448T3 (pl) | 2008-05-14 | 2009-05-07 | Miejsce wiązania HGFR o wysokim powinowactwie oraz sposoby identyfikacji jego antagonistów |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8404453B2 (pl) |
| EP (1) | EP2119448B1 (pl) |
| JP (1) | JP5623027B2 (pl) |
| KR (1) | KR101509263B1 (pl) |
| AT (1) | ATE513556T1 (pl) |
| BR (1) | BRPI0901502A2 (pl) |
| CA (1) | CA2665958C (pl) |
| CY (1) | CY1111853T1 (pl) |
| DK (1) | DK2119448T3 (pl) |
| EA (1) | EA017863B1 (pl) |
| ES (1) | ES2368603T3 (pl) |
| HR (1) | HRP20110643T1 (pl) |
| IL (1) | IL198545A0 (pl) |
| MX (1) | MX2009005049A (pl) |
| PL (1) | PL2119448T3 (pl) |
| PT (1) | PT2119448E (pl) |
| SG (1) | SG157312A1 (pl) |
| SI (1) | SI2119448T1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL198545A0 (en) | 2008-05-14 | 2011-07-31 | Metheresis Translational Res Sa | High affinity binding site of hgfr and methods for identification of antagonists thereof |
| EP3165538A1 (en) | 2010-11-03 | 2017-05-10 | Argen-X Nv | Anti c-met antibodies |
| GB2504139B (en) | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| EP2773660A2 (en) | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
| WO2013079973A1 (en) * | 2011-12-02 | 2013-06-06 | Di Cara Danielle Marie | Antibodies against hgf - receptor and uses |
| US11035860B2 (en) | 2014-11-20 | 2021-06-15 | Stichting Katholieke Universiteit | Auto-active and intracellular mutant of MET |
| EP3519440A4 (en) | 2016-09-29 | 2020-03-25 | Mitsubishi Tanabe Pharma Corporation | MONOCLONAL CMET BINDERS, ACTIVE SUBSTANCE CONJUGATES AND USES THEREOF |
| CN113567685B (zh) * | 2021-09-26 | 2022-05-17 | 瑞博奥(广州)生物科技股份有限公司 | 基于核酸适配体探针的hgfr识别方法及检测hgfr的试剂盒 |
| CN116121255A (zh) * | 2022-12-20 | 2023-05-16 | 中国科学院基础医学与肿瘤研究所(筹) | 一种结合hgfr蛋白的核酸适配体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3293823B2 (ja) * | 1991-05-10 | 2002-06-17 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | 肝細胞成長因子(hgf)レセプターの部分切除形態 |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| AU2760602A (en) | 2001-03-23 | 2002-09-26 | Agouron Pharmaceuticals, Inc. | Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereof |
| WO2007036945A2 (en) | 2005-09-30 | 2007-04-05 | Compugen Ltd. | Hepatocyte growth factor receptor splice variants and methods of using same |
| CN1922208A (zh) | 2003-12-11 | 2007-02-28 | 健泰科生物技术公司 | 用于抑制c-met二聚化及活化的方法和组合物 |
| US20060069019A1 (en) | 2004-05-06 | 2006-03-30 | Genentech, Inc. | Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use |
| US20060008844A1 (en) * | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| EP1911459B1 (en) * | 2005-07-28 | 2015-12-02 | AnGes MG, Inc. | Lymphangiogenesis promoter |
| ES2368864T3 (es) * | 2006-02-06 | 2011-11-23 | Metheresis Translational Research Sa | Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. |
| IL198545A0 (en) | 2008-05-14 | 2011-07-31 | Metheresis Translational Res Sa | High affinity binding site of hgfr and methods for identification of antagonists thereof |
-
2009
- 2009-05-04 IL IL198545A patent/IL198545A0/en not_active IP Right Cessation
- 2009-05-07 DK DK09159644.5T patent/DK2119448T3/da active
- 2009-05-07 ES ES09159644T patent/ES2368603T3/es active Active
- 2009-05-07 PT PT09159644T patent/PT2119448E/pt unknown
- 2009-05-07 SI SI200930068T patent/SI2119448T1/sl unknown
- 2009-05-07 AT AT09159644T patent/ATE513556T1/de active
- 2009-05-07 PL PL09159644T patent/PL2119448T3/pl unknown
- 2009-05-07 EP EP09159644A patent/EP2119448B1/en active Active
- 2009-05-11 KR KR1020090040560A patent/KR101509263B1/ko not_active Expired - Fee Related
- 2009-05-12 CA CA2665958A patent/CA2665958C/en not_active Expired - Fee Related
- 2009-05-12 MX MX2009005049A patent/MX2009005049A/es active IP Right Grant
- 2009-05-12 BR BRPI0901502-7A patent/BRPI0901502A2/pt not_active IP Right Cessation
- 2009-05-13 US US12/465,307 patent/US8404453B2/en not_active Expired - Fee Related
- 2009-05-13 EA EA200900537A patent/EA017863B1/ru not_active IP Right Cessation
- 2009-05-14 SG SG200903318-4A patent/SG157312A1/en unknown
- 2009-05-14 JP JP2009117725A patent/JP5623027B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-31 US US13/137,640 patent/US9121854B2/en not_active Expired - Fee Related
- 2011-08-31 US US13/137,641 patent/US20120115219A1/en not_active Abandoned
- 2011-09-07 HR HR20110643T patent/HRP20110643T1/hr unknown
- 2011-09-22 CY CY20111100917T patent/CY1111853T1/el unknown
-
2013
- 2013-02-21 US US13/773,497 patent/US9310377B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2119448B1 (en) | 2011-06-22 |
| US8404453B2 (en) | 2013-03-26 |
| KR101509263B1 (ko) | 2015-04-06 |
| MX2009005049A (es) | 2009-12-18 |
| BRPI0901502A2 (pt) | 2010-01-26 |
| JP5623027B2 (ja) | 2014-11-12 |
| EP2119448A1 (en) | 2009-11-18 |
| SG157312A1 (en) | 2009-12-29 |
| SI2119448T1 (sl) | 2012-02-29 |
| US20130183690A1 (en) | 2013-07-18 |
| DK2119448T3 (da) | 2011-09-26 |
| US20120108789A1 (en) | 2012-05-03 |
| PT2119448E (pt) | 2011-09-27 |
| US9121854B2 (en) | 2015-09-01 |
| US20120115219A1 (en) | 2012-05-10 |
| EA200900537A1 (ru) | 2009-12-30 |
| EA017863B1 (ru) | 2013-03-29 |
| HRP20110643T1 (hr) | 2011-10-31 |
| CY1111853T1 (el) | 2015-11-04 |
| ATE513556T1 (de) | 2011-07-15 |
| US20090298079A1 (en) | 2009-12-03 |
| US9310377B2 (en) | 2016-04-12 |
| KR20090118846A (ko) | 2009-11-18 |
| CA2665958C (en) | 2014-01-07 |
| AU2009201893A1 (en) | 2009-12-03 |
| CA2665958A1 (en) | 2009-11-14 |
| IL198545A0 (en) | 2011-07-31 |
| JP2009291191A (ja) | 2009-12-17 |
| ES2368603T3 (es) | 2011-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2119448T1 (sl) | HGFR povezovalno mesto z visoko afiniteto in postopki za identifikacijo njegovih anatagonistov | |
| ZA200908470B (en) | Polypeptides,antibody variable domains and antagonists | |
| ZA200908454B (en) | Polypeptides,antibody variable domains and antagonists | |
| UA95768C2 (ru) | Антагонисты мускариновых рецепторов ацетилхолина | |
| ZA200708756B (en) | Methods for treating and preventing fibrosis by IL-21R antagonists | |
| ZA200606056B (en) | Selected CGRP antagonists, methods for the production thereof and their use as medicaments | |
| MEP59208A (en) | Activin-actriia antagonists and uses for promoting bone growth | |
| DE602006007698D1 (de) | Maschine zur Zubereitung von Getränken mit Funktionsvorrichtung und Fußaufbau | |
| ATE554785T1 (de) | Modifizierte fgf-21 polypeptide und ihre verwendung | |
| GB2433937A (en) | Porous inorganic/organic hybrid materials with ordered domains for chromatographic separations and processes for their preparation | |
| ATE481099T1 (de) | Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten | |
| IL177922A0 (en) | Modified bouganin proteins, cytotoxins and methods and uses thereof | |
| IL189497A0 (en) | Selected cgrp antagonists, methods for the production thereof and their use as medicaments | |
| ZA201103588B (en) | Polypeptides,antibody variable domains & antagonists | |
| ZA201203052B (en) | Stable anti-tnfr1 polypeptides, antibody variable domains and antagonists | |
| MX2011004284A (es) | Metodo para tratar la hipertension arterial pulmonar. | |
| ZA200706361B (en) | Concrete sleeper and method for the production thereof | |
| WO2006016192A3 (en) | Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia | |
| UA98447C2 (ru) | АНТАГОНИСТЫ АКТИВИНА- ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ СОДЕЙСТВИЯ РОСТУ КОСТЕЙ | |
| GB0816782D0 (en) | Novel receptor & uses thereof | |
| MX2008002431A (es) | Metodos para el tratamiento contra ansiedad y para identificacion de agentes ansioliticos. | |
| GB0624687D0 (en) | Treatment of cachexia | |
| WO2009053895A3 (en) | Quinoline urotensin-ii receptor antagonists | |
| PL365618A1 (pl) | Przejazd przez torowisko, płyta przejazdu przez torowisko i sposób wykonania przejazdu przez torowisko | |
| PL386365A1 (pl) | Szyna osadzona w materiale tłumiącym do elastycznej zabudowy w bezpodsypkowej nawierzchni torowej i sposób wytwarzania szyny osadzonej w materiale tłumiącym |